Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings ...
Radial reports that teen depression is prevalent yet under-treated. Effective options include therapy, antidepressants, and ...
Alma details 10 research-backed apps that can help achieve New Year’s resolutions with structure, accountability, and ...
The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...
Mission Prep announces clinical programs for adolescents experiencing displaced anger, offering residential and outpatient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback